# A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

Source: https://onco.cc/trials/nct06940739/  
OnCo record `nct06940739` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IOV-3001 in melanoma and uveal melanoma, run by Iovance Biotherapeutics, Inc., now recruiting.

## Summary

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel is a phase 1/2 interventional study registered as NCT06940739 by Iovance Biotherapeutics, Inc., with 42 participants planned, started 2025-03-11 and due to reach its primary completion in 2032-06. Interventions recorded: IOV-3001.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06940739
- Phase: 1/2
- Setting: A Phase 1/2, Open-label Study of a Modified Interleukin-2 Fusion Protein (IOV-3001) in Participants With Previously Treated, Unresectable or Metastatic Melanoma Who Will Receive Lifileucel
- Sponsor: Iovance Biotherapeutics, Inc.
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT06940739: https://clinicaltrials.gov/study/NCT06940739

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- companies: [Iovance Biotherapeutics](https://onco.cc/companies/iovance/)

---
JSON: https://onco.cc/api/v1/entities/nct06940739.json